Health economic and quality of life considerations in the management of pain;Prise en charge de la douleur: Réflexions sur l'économie de la santé et la qualité de vie

Drugs

Volumn 63, Issue SPEC. ISS. 2, 2003, Pages 47-50

  Phillips, Ceri J ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PARACETAMOL;

ANALGESIC ACTIVITY; ANTINOCICEPTION; ARTHRITIS; ARTICLE; ASTHMA; CHRONIC PAIN; COST BENEFIT ANALYSIS; DECISION MAKING; DEPRESSION; DIABETES MELLITUS; DRUG EFFICACY; DRUG TOLERABILITY; HEALTH CARE COST; HEALTH CARE FINANCING; HUMAN; MIGRAINE; PRESCRIPTION; QUALITY OF LIFE; SIDE EFFECT;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; COST CONTROL; COST OF ILLNESS; DRUG COSTS; HUMANS; PAIN; QUALITY OF LIFE; RESOURCE ALLOCATION;

EID: 0142147051     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bolten W, Kempel-Waibel A, Pforringer W. Analysis of the cost of illness in backache. Med Klin 1998; 93: 388-93
2. van Jaarsveld CHM, Jacobs JWG, Schrijvers AJP, et al. Direct cost of rheumatoid arthritis during the first six years : a cost-of-illness study. Br J Rheumatol 1998; 37: 837-47
3. Department of Health. Prescription Cost Analysis for England 2000 [online]. Available from URL : htpp://www.doh.gov.uk/stats/pca2000.htm [Accessed 2002 October 30]
4. Belsey J. Primary care workload in the management of chronic pain : a retrospective cohort study using a GP database to identify resource implications for UK primary care. J Med Economics 2002; 5: 39-52
5. Walsh K, Cruddas M, Coggon D. Low back pain in eight areas of Britain. J Epidemiol Community Health 1993; 46: 227-30
6. Autret-Leca E, Bertin P, Boulu P, et al. La douleur aiguë de l'adulte en médecine générale. Enquête épidémiologique transversale nationale. Rev Prat 2002; 16 (572): 648-52
7. Kaarela K, Lehtinen K, Luukkainen R. Work capacity of patients with inflammatory joint diseases. An eight-year follow-up study. Scand J Rheumatol 1987; 16: 403-6
8. Maniadakis N, Gray A. The economic burden of back pain in the UK. Pain 2000; 84: 95-103
9. Gureje O, Von Korff M, Simon G, et al. Persistent pain and well-being : a World Health Organization study in primary care. JAMA 1998; 280: 147-51
10. Becker N, Thomsens AB, Olsen AK, et al. Pain epidemiology and health related quality of life in chronic non-malignant pain patients referred to a Danish multidisciplinary pain center. Pain 1997; 73: 393-400
11. Kosinski M, Kujawski SC, Martin R, et al. Health-related quality of life in early rheumatoid arthritis : impact of disease and treatment response. Am J Manag Care 2002; 8 (3): 231-40
12. Phillips CJ. The real cost of pain management. Anaesthesia 2001; 56: 1031-3
13. Tramer MR, Moore RA, Reynolds DJ, et al. Quantitative estimation of rare adverse events which follow a biological progression : a new model applied to chronic NSAID use. Pain 2000; 85: 169-82
14. Moore RA, Collins S, Carroll D, et al. Paracetamol with and without codeine in acute pain : a quantitative systematic review. Pain 1997; 70: 193-201
15. Smith LA, Moore RA, McQuay HJ, et al. Using evidence from different sources : an example using paracetamol 1000 mg plus codeine 60 mg. BMC Med Res Methodol 2001 Jan 10; (1): 1
16. Shamoon M, Hochberg MC. The role of acetaminophen in the management of patients with osteoarthritis. Am J Med 2001; 110: 46-9S
17. Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis : report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000; 59: 936-44
18. Rodriguez-Monguió R, Otero MJ, Rovira J. Assessing the economic impact of adverse drug effects. Pharmacoeconomics 2003; 21: 623-50
19. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee : 2000 Update. Arthritis Rheum 2000; 43: 1905-15
20. Brant KD, Bradley JD. Should the initial drug used to treat osteoarthritis pain be a nonsteroidal antiinflammatory drug ? J Rheumatol, 2001; 28: 467-73
21. Courtney P, Doherty M. Key questions concerning paracetamol and NSAIDs for osteoarthritis. Ann Rheum Dis 2002; 61: 767-73
22. Rahme E, Joseph L, Kong SX, et al. Gastrointestinal health care resource use and costs associated with nonsteroidal anti-inflammatory drugs versus acetaminophen : retrospective cohort study of an elderly population. Arthritis Rheum 2000; 43: 917-24
23. Audit Commission. Anaesthesia under examination. London : Audit Commission, 1997
24. Rawal N, Allvin R, for the EuroPain Acute Pain Working Party. Acute pain services in Europe : a 17-nation survey of 105 hospitals. Eur J Anaesthesiol 1998; 15: 354-63
25. Hopton JL, Dlugolecka M. Patients' perceptions of need for primary health care services : useful for priority setting? BMJ 1995; 310: 1237-40
26. Loesner JD. Economic implications of pain management. Acta Anaesthesiol Scand 1999; 43: 957-9